Navigation Links
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Date:9/21/2007

imulating the body's ability to produce insulin in response to elevated levels of blood sugar, inhibiting the release of a hormone called glucagon following meals, slowing the rate at which nutrients are absorbed into the bloodstream and reducing food intake.

About Diabetes

Diabetes affects more than 20 million in the United States and an estimated 246 million adults worldwide(4,5). Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States and costs approximately $132 billion per year in direct and indirect medical expenses(6).

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen(7).

Important Safety Information for BYETTA(R) (exenatide) injection

BYETTA improves glucose (blood sugar) control in patients with type 2 diabetes who are taking metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems with the stomach or food digestion, or those who have severe kidney disease. Before using BYETTA, patients should tell their healthcare provider if they are pregnant, plan to become pregnant, or are breastfeeding. BYETTA has not been studied in children.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is most common when first starting BYETTA, but decreases over time in most patients. BYETTA may reduce
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... MONTREAL , Nov. 24, 2014 /PRNewswire/ - Milestone ... clinical trial conducted in Melbourne, Australia ... antagonist for the potential treatment of paroxysmal supraventricular ... formulation of MSP-2017 was well tolerated at single ... an excellent safety profile, desirable PK properties including ...
(Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
(Date:11/24/2014)... , Nov. 24, 2014  Surgical Theater, LLC, announced ... November 24 th opening of Europe,s ... Neurologico Nazionale "C. Besta." The SuRgical Planner (SRP) and ... at the event for their 3D navigation and augmented ... Joshua Bederson , Professor and Chair, Department of Neurosurgery ...
Breaking Medicine Technology:Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3Relmada Therapeutics To Present At LD MICRO Conference 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... Biogen Idec (NASDAQ: BIIB),and Elan Corporation, plc (NYSE: ... Prescribing Program(TM) and TYGRIS safety study,confirm the safety ... presented at the 59th annual meeting,of the American ... data that showed that TYSABRI has a sustained ...
... WIRE)--May 3, 2007 - Insmed Inc.,(Nasdaq:INSM) today announced ... the company's drug, IPLEX(TM), in,patients with myotonic muscular ... being conducted at,the University of Rochester School of ... with doses of IPLEX up to 1,mg/kg/day in ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 2Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 3Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 4Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 5Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 6Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4
(Date:11/26/2014)... Gone are the days when throngs of ... Friday, which signifies the beginning of the Christmas shopping season. ... carts in the comfort of their homes or on the ... is going to be an occasion with one of the ... $2.48 billion in revenue for online retailers according to Adobe ...
(Date:11/26/2014)... HILLS, CA (PRWEB) November 26, 2014 With ... costing thousands of dollars, the prosthodontists at the Anacapa Dental ... paying for dental procedures can be daunting for some. , ... pay for the procedures they offer. , “No dentist wants ... and beautiful set of teeth,” said Dr. Mamaly Reshad, partner ...
(Date:11/26/2014)... VA (PRWEB) November 26, 2014 ... greater effectiveness in containing and stopping Ebola, improve ... stability in healthcare systems in West Africa. ... Systems to Stop Ebola: Anthropologists Offer Insights,” will ... by the American Anthropological Association (AAA), Fri., Dec. ...
(Date:11/26/2014)... 2014 Louisiana Back Institute, leaders ... in minimally invasive spine surgery, announces today the ... rapidly growing provider network of orthopedic spine surgeons ... with the network’s continuing success providing the most ... residents who are suffering from orthopedic spine conditions ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Vultures have ... bacteria they ingest when eating dead animals, researchers report. ... bacteria found on the faces and in the guts ... United States. On average, the faces of the vultures ... with 76 in their guts, the study found. ...
Breaking Medicine News(10 mins):Health News:2014 Best Friday Deals Revealed by Top10InAction 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... Nov. 12 You,re visiting the dentist for what you ... she says you need a root canal. Though it,s a ... in the chair, you may have several questions and feel ... root canals for quite some time. The Pennsylvania Dental Association ...
... Healthcare is an industry faced with unprecedented uncertainty. ... overcome the noise and clearly communicate relevant and timely ... company Griffin York & Krause (GY&K) reaffirmed its commitment ... been honored with six national CardioVascular Advertising (CVA) Awards. ...
... certification pilot significantly expands chemical emissions and content ... from products used in multiple environments. ... (GEI) announces the launch of GREENGUARD Premier(SM), a ... indoor air quality criteria, additional chemical emission requirements ...
... 12 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: ... declared a regular quarterly dividend of $.11 per share of ... The dividend will be payable December 15, 2009, to shareholders ... in 1984 Mesa Labs has maintained strong cash positions and ...
... Christiana Care Health System,s Helen F. Graham ... nation to submit specimens to the Biospecimen Core Resource ... project is part of a sweeping initiative by the ... and even prevent cancer in the future. , ...
... holds hope of better treatment for muscular dystrophy, ... Researchers are reporting that injections of genes into the ... size and strength without side effects. , The ... gene-therapy findings, though preliminary, might someday lead to better ...
Cached Medicine News:Health News:Painful Root Canals Are a Thing of the Past 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 3Health News:GREENGUARD Launches Comprehensive Health-Based Certification Pilot Program 2Health News:Christiana Care First Community Hospital to Submit Samples to Cancer Genome Atlas Project 2
The Lang Stereotest was created to simplify stereopsis screening in children. It is based on two principles: random dots and cylindrical gratings. The Lang Stereotest I measures disparities: Star 600...
8 X 1 Red Filter. Color Filters are designed to filter out all other color regions of the visible spectrum except the specified color. Color Filters are excellent for contrast enhancement and color r...
Maxi-Lite diagnostic penlight features a twist-on backswitch....
Features a twist-on backswitch with a diffused, cobalt blue, light beam. Packaged with fluorescein strips....
Medicine Products: